The company will provide manufacturing services through 2031 in deals worth over USD 668 million Samsung Biologics’ cumulative contract value for 2024 surpasses USD 4 billion with latest deals INCHEON, South Korea, Nov. 19, 2024 /PRNewswire/ — Samsung Biologics (KRX: 207940.KS), a global…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.